However, the treatment decision-making process remains challenging, especially in HR-positive (HR+)/HER2-negative (HER2-) BC at intermediate risk, where the additional benefit of chemotherapy (CT) over the use of endocrine therapy (ET) alone is largely unclear. Here, ERBB2 is linked to breast cancer.